Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.38 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705578 | 0.84 | PKM (0.62) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL22306542 | 0.82 | PKM (0.44) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL22290979 | 0.79 | PKM (0.45) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL22290714 | 0.79 | PKM (0.45) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL1504624 | 0.75 | PKM (0.60) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL22290685 | 0.75 | CA12 (0.44) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| Hydrochloric Acid SCHEMBL1891433 | 0.74 | PKM (0.59) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL12465536 | 0.72 | PKM (0.56) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL23245987 | 0.72 | PKM (0.56) | PKMALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL22306468 | 0.72 | MEN1 (0.42) | PKMALDH1A1KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486262-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12383555-B2 | Methods of treating cancers | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| WO-2025099307-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-05-15 | — | — | WO | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119677738-A | Compounds and uses thereof | 福宏治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240374605-A1 | METHODS OF TREATING CANCER | FOGHORN THERAPEUTICS INC. | 2024-11-14 | — | — | US | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024191268-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 현대약품 주식회사 | 2024-09-19 | — | — | WO | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2021155262-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210230154-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210230154-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160100-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230154-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | PKM 2012/4885ALDH1A1 2571/4885TUBB4A 473/4885 |
| US-20240374605-A1 | METHODS OF TREATING CANCER | CARM1, SMARCC1, RB1 | PKM 1344/4885ALDH1A1 2174/4885TUBB4A 1569/4885 |
| US-12486262-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | PKM 2012/4885ALDH1A1 2571/4885TUBB4A 473/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | PKM 2012/4885ALDH1A1 2571/4885TUBB4A 473/4885 |
| US-12383555-B2 | Methods of treating cancers | MCL1, BRPF3, VHL | PKM 2715/4885ALDH1A1 1754/4885TUBB4A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.